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Available online 27 February 2016Irisin, a myokine released during exercise, promotes browning of subcutaneous adipose tissue and regulates en-
ergy homeostasis. Although exercise constantly reduces blood cholesterol, whether irisin is involved in the reg-
ulation of cholesterol remains largely unknown. In the present study, subcutaneous infusion of irisin for 2 weeks
induced a reduction in plasma and hepatic cholesterol in high fat diet-induced obese (DIO) mice. These alter-
ationswere associatedwith an activation of 5′AMP-activated protein kinase (AMPK) and inhibition of sterol reg-
ulatory element-binding transcription factor 2 (SREBP2) transcription and nuclear translocation. In primary
hepatocytes from either lean or DIOmice, irisin signiﬁcantly decreased cholesterol content via sequential activa-
tion of AMPK and inhibition of SREBP2. Suppression of AMPK by compound C or AMPKα1 siRNA blocked irisin-
induced alterations in cholesterol contents and SREBP2. In conclusion, irisin could suppress hepatic cholesterol
production via a mechanism dependent of AMPK and SREBP2 signaling. These ﬁndings suggest that irisin is a
promising therapeutic target for treatment of hypercholesterolemia.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Liver1. Introduction
Irisin was recently identiﬁed as a myokine proteolytically cleaved
from ﬁbronectin type β domain containing 5 (FNDC5) (Bostrom et al.,
2012). Exercise could induce irisin expression and secretion into circu-
lation to exert its effects on browning of subcutaneous adipose tissue
(Bostrom et al., 2012; Wu et al., 2014; Shan et al., 2013; Rodriguez
et al., 2015; Lee et al., 2014; Wu et al., 2012), as well as subsequent im-
provement of obesity (Huh et al., 2014; Miyamoto-Mikami et al., 2015)
and its related disorders such as type 2 diabetes (Xiong et al., 2015;
Bostrom et al., 2012; Vaughan et al., 2014). These observations suggest
that irisin may contribute to the regulation of energy homeostasis and
thus is the potential target for therapy of metabolic dysfunction associ-
ated with obesity. This concept is further supported by clinical observa-
tions. Circulating irisin was found to be reduced in obese human (Yan
et al., 2014; Moreno-Navarrete et al., 2013; Duran et al., 2015; Hou
et al., 2015) and rodents (Bilski et al., 2015) and in patients with diabe-
tes (Espes et al., 2015; Li et al., 2015a; Choi et al., 2013; Xiang et al.,K, 5′ AMP-activated protein ki-
tion factor 2; FNDC5,ﬁbronectin
l chow diet; HFD, high-fat diet;
und C; siRNA, small interfering
y and Pathophysiology, Peking
, yyyrrrlll@126.com (R. Yu),
watibieke), liziru@umich.edu
. This is an open access article under2014; Liu et al., 2013; Duran et al., 2015; Moreno-Navarrete et al.,
2013; Kurdiova et al., 2014), or chronic kidney disease (Wen et al.,
2013; Ebert et al., 2014). Conversely, it was positively associated with
endothelium-dependent vasodialation (Xiang et al., 2014; Hou et al.,
2015; Zhu et al., 2015) and myocardiac infraction in type 2 diabetes
(Aronis et al., 2015; Hou et al., 2015).
The relationship between irisin and lipid metabolism has been con-
troversial. Evidence suggesting a negative relation between irisin and
lipid dysregulation has been emerging. Circulating levels of irisin were
negatively correlated with total cholesterol, LDL cholesterol and triglyc-
eride (Huh et al., 2012; Zhang et al., 2013; Ebert et al., 2015; Duran et al.,
2015) and intrahepatic triglyceride contents in obese adults (Zhang
et al., 2013), while positively correlated with HDL cholesterol. In obese
human, diet intervention-induced reduction in glucose and triglyceride
was greater in those with higher baseline irisin levels (Lopez-Legarrea
et al., 2014). Lentivirus-mediated overexpression of FNDC5 or subcuta-
neous perfusion of irisin reduced blood triglyceride, cholesterol, free
fatty acid and glucose in obesemice (Xiong et al., 2015). Further studies
in vitro showed an inhibitory effect of irisin on palmitic acid (PA)-in-
duced lipid accumulation and lipogenic markers via inhibition of pro-
tein arginine methyltransferase-3 in AML12 cells and mouse primary
hepatocytes (Park et al., 2015). Other studies have suggested a positive
relation between irisin and lipid dysfunction. Circulating irisin levels
were positively associated with total cholesterol, LDL cholesterol and
fasting fatty acids in a Chinese population independent of BMI (Tang
et al., 2015) and in women with polycystic ovary syndrome (Li et al.,
2015b). Energy restriction induced depletion of irisin was associated
with decrease in total cholesterol, total cholesterol/HDL-cholesterolthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
140 H. Tang et al. / EBioMedicine 6 (2016) 139–148ratio, LDL-cholesterol and apolipoprotein B, independent of changes in
bodyweight (de la Iglesia et al., 2014). In adults at higher cardiovascular
risk, irisin was negatively associated with HDL cholesterol and large
HDL particles (Panagiotou et al., 2014). In addition, serum irisinwas sig-
niﬁcantly higher in patients with nonalcoholic fatty liver disease (Choi
et al., 2014) and in patients with portal inﬂammation (Polyzos et al.,
2014). Moreover, plasma irisin was positively related to total cholester-
ol in adults with Prader–Willi Syndrome (Hirsch et al., 2015). Neverthe-
less, other studies have found no signiﬁcant association of irisin with
raised triglyceride and reducedHDL in obese adultswithmetabolic syn-
drome (Yan et al., 2014) or with NAFLD (Polyzos et al., 2015). In addi-
tion, irisin has been demonstrated to exercise no effect on either
lipolysis in 3T3-L1 adipocytes or fatty acid metabolism in HepG2 hepa-
tocytes (Wang et al., 2015). Therefore, further investigation is necessary
to deﬁne the role of irisin in lipid metabolism.
Here we reported that irisin suppressed cholesterol synthesis in he-
patocytes through the activation of 5′ AMP-activated protein kinase
(AMPK) and subsequent inhibition of transcription and nuclear translo-
cation of sterol regulatory element-binding transcription factor 2
(SREBP2).
2. Materials and Methods
2.1. Materials
Antibodies used in the study were: pAMPKα Thr172 (2535, CST,
Beverly, MA, USA) and AMPKα (2532, CST), SREBP2 (ab30682,
Abcam, Cambridge, MA, USA) and β-actin (AT 0001, Milwaukee,
WI). Donkey-anti-rabbit Alexa Fluor® 488-IgG (711-545-152) was
from Jackson ImmunoResearch (West Grove, PA, USA). IRDye-
conjugated afﬁnity puriﬁed anti-rabbit and anti-mouse IgGs were
purchased from Rockland (Gilbertsville, PA, USA). Irisin (067-16)
was from Pheonix (Burlingame, CA, USA). Recombinant irisin-Fc
and Fc control were expressed in HEK293 cells (Abgent, Nanjing,
China) and puriﬁed by high-performance liquid chromatography.
Oleic acid (OA), collagenase IV and compound C were purchased
from Sigma Aldrich (St. Louis, MO, USA). Alzet microosmotic
pumps (1002) were from DURECT Corporation (Cupertino, CA,
USA). Aprotinin was purchased from Amersham Biosciences (Pitts-
burgh, PA, USA). Triglyceride and cholesterol Colorimetric Assay
Kits were from Cayman Chemical Company (Ann Arbor, MI, USA).
BCA protein quantitative assay kit was from Applied Gene (Beijing,
China).
2.2. Animals
Animals were handled in accordance with the Guide for the Care
and Use of Laboratory Animals published by the US National Insti-
tutes of Health (NIH publication no. 85-23, revised 1996). All exper-
imental protocols were approved by the Animal Care and Use
Committee of Peking University. Mice were housed in standard plas-
tic rodent cages and maintained in a regulated environment (24 °C,
12-h light and 12-h dark cycle with lights on at 7 AM and off at
7 PM). Four-week-old male C57BL/6J mice were fed a normal chow
diet (NCD) or a high-fat diet (HFD) (60% fat, D12492; Research
Diets, New Brunswick, NJ, USA) ad libitum for 14 weeks followed
by 2-week subcutaneous perfusion of irisin-Fc or Fc control at a
dose of 12 nmol/d·kg body weight (BW). Food intake was measured
and averaged for 2 mice in one cage. Mice were sacriﬁced without
fasting after anesthesia by intraperitoneal injection of pentobarbital
sodium at 70 mg/kg BW. Liver was frozen in liquid nitrogen and
stored in −80 °C freezer for future experiments. Blood samples
were transcardially collected and immediately transferred to chilled
polypropyrene tubes containing EDTA-Na2 (12.5 mg/mL) and
aprotinin (1000 units/mL) and centrifuged at 4 °C. The plasma was
separated and stored at−80 °C before use.2.3. Implantation of Osmotic Minipumps
Theminipumps were placed in a Petri dish with sterile 0.9% saline
at 37 °C for at least 4 h, then ﬁlled with the test agent before implan-
tation. Mice were anesthetized with pentobarbital sodium and a
1 cm incision was made in the back skin through which an Alzet os-
motic minipump (model 1002) ﬁlled with irisin-Fc or Fc control was
implanted subcutaneously.
2.4. Isolation and Culture of Primary Hepatocytes
Twelve-week old lean or diet-induced-obese (DIO) C57BL/6J
mice were anesthetized with pentobarbital sodium at 60 mg/kg
BW and injected intraperitoneally with 1000 IU heparin. After lapa-
rotomy, the portal vein was cannulated. The liver was perfused
with 20 mL of pre-warmed 37 °C Hanks buffer, followed by 20 mL
of 0.02% collagenase IV at a ﬂow rate of 2 mL/min. After perfusion,
liver tissues were removed and washed with warm Hanks buffer.
Liver capsule was removed, and hepatic tissues dispersed and incu-
bated in 20 mL of 0.01% collagenase IV in a shaking water bath at
37 °C for 20 min. Cell suspension was then ﬁltered through 80-μm
nylonmesh twice, centrifuged at 500 rpm [SorvallRT7 Benchtop Cen-
trifuge with RTH 250 rotor (Ramsey, MN)] and washed twice with
DMEM to remove tissue dissociation enzymes, damaged cells, and
nonparenchymal cells. Dispersed hepatocytes were counted and
seeded at a concentration of 1–2 × 105 cells per well in a 6-well
plate containing 2 mL of high glucose DMEM supplemented with
10% (vol/vol) FBS. Cells were cultured at 37 °C in a humidiﬁed atmo-
sphere of 5% (vol/vol) CO2. Culture medium was changed to high
glucose DMEM supplemented with 2% (vol/vol) FBS 24 h later. Hepa-
tocytes were then treated with 10 nM irisin for 20 min or 3, 6, 12 and
24 h as indicated in the absence or presence of 125 μMOA.Where in-
dicated, compound C was added 1 h prior to the addition of irisin and
OA.
2.5. Cell Culture and siRNA Transfection
HepG2 cells were cultured with high glucose DMEM supplemented
with 10% (vol/vol) FBS at 37 °C in a humidiﬁed atmosphere of 5% (vol/
vol) CO2. Cells were seeded in a 12-well plate at 30–50% conﬂuency.
siRNA was transfected using siRNA-Mate (G04002, GenePharma,
Shanghai, China) following themanufacturer's instructions. Cultureme-
dium was changed to high glucose DMEM supplemented with 2% (vol/
vol) FBS 48 h later. Cells were stimulated with 10 nM irisin for 12 h or
24 h as indicated. siRNA sequences were for Scrambled sense: 5′-
UUCUCCGAACGUGUCACGUTT-3′, antisense: 5′-ACGUGACACGUUCG
GAGAATT-3′; for siAMPKα1 sense: 5′-CGGGAUCAGUUAGCAACUATT-
3′, antisense: 5′-UAGUUGCUAACUGAUCCCGTT-3′.
2.6. Measurements of Triglyceride and Cholesterol Content
Twentymilligram liver tissueswere homogenized in 1mL of 2:1 chlo-
roform/methanolmix on ice and placed at 4 °C for 18 h. Two hundredmi-
croliters of distilled water was added to the homogenates. The mixture
was vortexed, then centrifuged for 10 min at 3000 rpm, 4 °C. The lower
phase was collected, lyophilized and resolved in 5% Triton X-100 in PBS
for measurements of lipids. Primary hepatocytes were homogenated ac-
cording to manufacturer's instructions, and the supernatant was used
for lipid detection. Plasma, hepatic and primary hepatocytes triglyceride
and cholesterol were measured according to the manufacturer's instruc-
tions. Values were normalized to protein concentration.
2.7. Western Blot Analysis
Liver tissues and primary hepatocytes were homogenized in
RIPA lysis buffer. Proteins were subjected to SDS/PAGE separation
Fig. 1. Effects of irisin on adiposity. Four-week-old C57 BJ/L6 mice were fed NCD or HFD for 16 weeks. During the last 2 weeks, irisin was infused into mice subcutaneously at a dose of
12 nmol/d·kg body weight via an osmotic pump. a. Body weight. b. Cumulative food intake. c. Organ mass. d. HE staining of eWAT and sWAT. e. OGTT and ITT. #P b 0.05 vs HFD Fc.
N = 6.
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brane. Membranes were incubated for 1 h at room temperature with
5% fat-free milk in Tris-buffered saline containing Tween 20, followed
by incubation overnight at 4 °C with primary antibodies. Speciﬁc reac-
tionwas detected by using IRDye-conjugated second antibody and visu-
alized using the Odyssey infrared imaging system (LI-COR Biosciences,
Lincoln, NE, USA).2.8. Gene Expression Analysis
For analyses of gene expression, RNA was extracted from mouse
liver or primary hepatocytes using RNATrip (Applied Gene, Beijing,
China) and reverse-transcribed into cDNAs using the First-Strand Syn-
thesis System for RT-PCR kit (Fermentas, Lafayette, CO, USA). SYBR
Green-based quantitative real time-PCR was performed using the
Mx3000 multiplex quantitative PCR system (Stratagene, La Jolla, CA,
USA). Triplicate samples were collected for each experiment to deter-
mine relative expression levels. All gene expression levels were normal-
ized by β-actin. Sequences for the primer pairs used in this study are
listed in Supplemental Table 1.2.9. Immunoﬂuorescent Staining
Liver frozen sections and isolated hepatocytes were washed with
PBS three times and ﬁxed in 4% paraformaldehyde for 20 min, followed
by permeabilizationwith 0.05% Triton X-100 in PBS for 20min. Nonspe-
ciﬁc bindingwere blocked by 4% goat serum for 1 h. Liver slides or hepa-
tocytes were then incubated with anti-SREBP2 (1:100) overnight at
4 °C. After 3-timewash in PBS, the liver slides or hepatocyteswere incu-
bated with anti-rabbit Alex ﬂuor488-conjugated IgG (1:500) at room
temperature for 1 h followed by incubation of Hoechst for 15min. Fluo-
rescent signals were observed and captured under a confocal laser-
scanning microscope (Leica). The signal intensity was analyzed by soft-
ware Leica Qwin 2.6.
2.10. Nuclear Fraction Extraction
Primary hepatocytes cultured in a 6-well plate were washed twice
with cold PBS and collected in 100 μL of 1× hypotonic buffer containing
20mMTris–HCl of pH 7.4, 10mMNaCl and 3mMMgCl2 followed by in-
cubation on ice for 15 min. Five microliter detergent (10% NP40) was
added and vortexed for 10 s, then centrifuged for 10 min at 3000 rpm
at 4 °C. The supernatant contained the cytoplasmic fraction. The
Fig. 2. Effects of irisin on plasma and hepatic lipid contents. C57 BJ/L6 mice fed NCD or HFD for 14weeks were infusedwith irisin at a dose of 12 nmol/d·kg bodyweight for twoweeks. a.
Plasma cholesterol and triglyceride contents and FPLC-separated lipoprotein fractions. b. Hepatic total and esteriﬁed- cholesterol and triglyceride contents. c. Oil red O staining of liver and
lipid area quantiﬁcation. d. HE staining of liver. *P b 0.05 vs NCD Fc; #P b 0.05, ##P b 0.01, ###P b 0.001 vs HFD Fc. N = 6. See also Supplemental Fig. 1.
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buffer (containing 100 mM Tris–HCl of pH 7.4, 2 mM Na3VO4, 100 mM
NaCl, 1% Triton X-100, 1 mM EDTA, 10% glycerol, 1 mM EGTA, 0.1%
SDS, 1 mM NaF, 0.5% deoxycholate and 20 mM Na4P2O7) pre-
supplemented with 1 mM PMSF and protease inhibitor cocktail and
ultrasonicated, followed by centrifugation for 30 min at 14,000 g, 4 °C.
Supernatant was collected as the nuclear fraction.
2.11. Fast-protein Liquid Chromatography Fractionation of Lipoproteins
Two hundredmicroliter of plasma aliquots were pooled from 6 mice
per group and applied to Tricorn high-performance Superose S-6 10/
300GL columns using a fast-protein liquid chromatography system
(Amersham Biosciences, Marlborough, MA, USA), followed by elu-
tion with FPLC buffer (pH 7.4, containing 8.775 g NaCl, 3.58 g
Na2HPO4·12H2O and 37.2 g EDTA in 1 L distilled water) at a constant
ﬂow rate of 0.75 mL/min. Eluted fractions (500 μL) were assayed for
triglyceride and cholesterol concentrations.
2.12. Oil Red O Staining
Liver frozen sections were rinsed in PBS three times, then ﬁxed with
4% paraformaldehyde for 10 min. After washing, slices were incubatedin 0.3% oil-red staining solution for 1 h at room temperature. Samples
were then counterstained with hematoxylin for 30 s, followed by
wash in running water for 60 min. All slides were mounted with 90%
glycerol and stored at 4 °C before observation. The signal intensity was
analyzed by software QWin 2.6.2.13. Glucose Tolerance Test and Insulin Tolerance Test
For oral glucose tolerance tests, mice were fasted for 16 h
followed by intragastric administration of glucose (3 g/kg BW)
by gavage. For insulin tolerance tests, mice were fasted for 6 h,
followed by intraperitoneal injection of insulin (1 IU/kg BW).
Blood was drawn from the tail vein at 0, 15, 30, 60, 90 and
120 min, and blood glucose concentrations were detected
immediately.2.14. Statistical Analysis
All data are expressed as mean ± SEM. Statistical difference was
determined by Student's t test or two-way ANOVA and post-hoc
Bonferroni test. P b 0.05 was considered signiﬁcant.
Fig. 3. Effects of irisin on cholesterol metabolism related genes inmouse liver. Four-week-
old C57 BJ/L6 mice were fed NCD or HFD for 16 weeks. During the last 2 weeks, irisin was
infused into mice subcutaneously at a dose of 12 nmol/d·kg body weight via an osmotic
pump. Hepatic mRNA expression was analyzed via real-time PCR. a. mRNA levels of
cholesterol synthesis related genes. b. mRNA levels of cholesterol transport and
degradation related genes. c. mRNA levels of triglyceride synthesis related genes. d.
mRNA levels of fatty acid synthesis and oxidation related genes. *P b 0.05, **P b 0.01 vs
NCD Fc; #P b 0.05, ##P b 0.01, ###P b 0.001 vs HFD Fc. N = 6.
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3.1. Amelioration of Obesity by Irisin
Four-week-old C57 BJ/L6 mice were fed NCD or HFD for 16 weeks.
During the last 2 weeks, irisin was infused into mice subcutaneously
at a dose of 12 nmol/d·kg BW via an osmotic pump. As shown in Fig.
1, irisin decreased bodyweight of DIOmice relative to animals receiving
vehicle control (Fig. 1a), while demonstrated no effect on food intake
(Fig. 1b). Organ mass for liver, epididymal white adipose tissue
(eWAT) and subcutaneous WAT (sWAT) was also decreased by irisin
in DIO mice (Fig. 1c). The reduction in WAT mass was associated with
a decrease in the size of adipocytes in eWAT and sWAT, especially in
the DIO group (Fig. 1d), as well as induction of multilocular lipid drop-
lets in adipocytes in animals fed NCD (Fig. 1d). Interestingly, glucose in-
tolerance in DIO mice was ameliorated by irisin, whereas insulin
sensitivity remained unaltered (Fig. 1e).
3.2. Effect of Irisin on Plasma and Hepatic Cholesterol Contents
Since irisin improved adiposity in mice, we next examined the
change of lipid levels. As shown in Fig. 2, irisin signiﬁcantly decreasedplasma total, VLDL-, LDL-, HDL-cholesterol, and hepatic levels of total
and esteriﬁed cholesterol in DIO mice, while demonstrated no consis-
tent effect on plasma and hepatic triglyceride (Fig. 2a, b). Consistently,
Oil red O staining showed reduced fat deposition in hepatocytes in
mice treated with irisin relative to the control (Fig. 2c). Histological ex-
amination demonstrated a signiﬁcant reduction of vacuolation in the
liver of DIO mice (Fig. 2d). Similar results were observed for synthetic
irisin (Supplemental Fig. 1). Collectively, irisin reduced plasma and he-
patic cholesterol contents in DIO mice.
3.3. Effect of Irisin on Cholesterol Metabolism Related Genes in Mouse Liver
Genes related to lipid synthesis, transport and degradation in the
liver were next determined. As shown in Fig. 3a, mRNA levels of
SREBP2 (Srebf2), 3-hydroxy-3-methylglutaryl-CoA reductase (Hmgcr),
3-hydroxy-3-methylglutaryl-Coenzyme A synthase (Hmgcs) and the
liver X receptorα (LXRα, Nr1h3)), which are all important in cholester-
ol synthesis, were signiﬁcantly decreased by irisin treatment. In addi-
tion, peripheral infusion of irisin signiﬁcantly suppressed mRNA levels
of low density lipoprotein receptor (Ldlr) that recognizes and uptakes
LDL-cholesterol, while increased mRNA levels of ATP-binding cassette
gene 5 (Abcg5) and Abcg8which form a heterodimer tomediate choles-
terol secretion (Fig. 3b). No signiﬁcant effect was observed for Cyp7a1
and Cyp8b1 which are critical for bile acid synthesis from cholesterol
(Fig. 3b). Further, no change in Fgf21mRNA expression (Supplemental
Fig. 2a) and AKT phosphorylation (Supplemental Fig. 2b)were detected
after irisin infusion. As for genes related to triglyceride metabolism,
irisin demonstrated only modest inhibition for triglyceride synthesis-
related genes such as SREBP1c (Srebf1c), glycerol-3-phosphate acyl-
transferase (Gpam), and diacylglycerol O-acyltransferase 1 (Dgat1)
(Fig. 3c). mRNA levels of genes critical for fatty acid synthesis including
acetyl-Coenzyme A carboxylase alpha (Acaca), fatty acid synthase
(Fasn), and stearoyl-Coenzyme A desaturase 1 (Scd1), and β-oxidation
such as peroxisome proliferator-activated receptorα (Pparα) and carni-
tine palmitoyltransferase 1A (Cpt1α) remained unchanged (Fig. 3d).
Therefore, irisin decreased mRNA expression of genes related to the
synthesis of cholesterol, while increased those genes related to choles-
terol excretion.
3.4. Direct Effects of Irisin on Cholesterol Synthesis in Cultured Primary
Hepatocytes
To determine whether irisin directly acts on hepatocytes to regulate
cholesterol synthesis, we treated the primary hepatocytes isolated from
either lean (Fig. 4a–d) or DIO (Fig. 4e–g)micewith irisin. OAwas previ-
ously reported to increase cholesterol synthesis and HMGCR activity in
hepatocytes (Goh and Heimberg, 1976; Gibbons et al., 1986). We thus
treated the cultured hepatocytes with OA in our experiment. OA-
induced increase in cholesterol contentwas reversed by irisin treatment
in primary hepatocytes from either lean (Fig. 4a) or DIO (Fig. 4e) mice,
while no signiﬁcant changewas observed for triglyceride in hepatocytes
from DIO mice (Fig. 4e). We next examined the mRNA expression of
genes related to cholesterol metabolism in hepatocytes from lean
mice. Consistent with the alteration in mouse liver, mRNA levels of
Srebf2, Hmgcr, Hmgcs and Ldlr were decreased by irisin treatment in
the presence or absence of OA in cultured hepatocytes (Fig. 4b). Howev-
er, mRNA levels of LXRα, Abcg5, Abcg8, Cyp7a1 and Cyp8b1were not af-
fected (Fig. 4c). mRNA levels of genes related to triglyceridemetabolism
including Srebf1c, Dgat1, and Cpt1α were not affected (Fig. 4d). Similar
observation was detected in hepatocytes from DIO mice. mRNA levels
of Srebf2,Hmgcr,Hmgcs and LXRαwere decreased by treatment of hepa-
tocytes with irisin in the presence or absence of OA (Fig. 4f). However,
genes related to cholesterol uptake (Ldlr, Pcsk9 and ApoB), secretion
(Abca1, Abcg5 and Abcg8) and bile acid synthesis (Cyp7a1 and Cyp8b1)
remained largely unaltered (Fig. 4g). Furthermore, conditionedmedium
fromC2C12myotubes infectedwith Ad-FNDC5blocked theOA-induced
Fig. 4.Direct effects of irisin on cholesterol synthesis in cultured primary hepatocytes. Primary hepatocytes were isolated from either lean (Fig. 4A–D) or DIO (Fig. 4E–G)mice and treated
with irisin (10 nM) in the presence or absence of OA (125 μM) for 24h. a. Cholesterol and triglyceride contents in primary hepatocytes from leanmice. b–d.mRNA levels of genes related to
cholesterol synthesis (b), transport and degradation (c), triglyceride synthesis, fatty acid synthesis and β-oxidation (d) in hepatocytes from lean mice. e. Cholesterol and triglyceride
contents in primary hepatocytes from DIO mice. f and g. mRNA levels of genes related to cholesterol synthesis (f), transport and degradation (g) in hepatocytes from DIO mice.
*P b 0.05, **P b 0.01, ***P b 0.001 vs control; #P b 0.05, ##P b 0.01, ###P b 0.001 vs OA. h. Primary hepatocytes were treated with conditioned medium from C2C12 myotubes infected
with Ad-GFP or Ad-FNDC5 for 24 h. Cholesterol and triglyceride contents were measured. **P b 0.01 vs Ad-GFP; #P b 0.05, ###P b 0.001 vs Ad-GFP + OA. Shown is the representative
of at least 3 experiments.
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mice, while demonstrated negligible effect on triglyceride (Fig. 4h). All
these results indicated that irisin inhibited the cholesterol synthesis in
hepatocytes.
3.5. AMPK-SREBP2 Dependent Effects
AMPK-SREBP2 signaling is critical for the regulation of cholesterol
metabolism (Quan et al., 2013; Elhanati et al., 2013). We thus investi-
gated whether this signaling mechanism mediates the suppression of
cholesterol synthesis induced by irisin in hepatocytes. As shown in Fig.
5a, irisin at a dose of 10 nM signiﬁcantly increased the phosphorylationof AMPKα Thr172 in a time-dependent manner. This alteration was as-
sociatedwith a decrease in the nuclear translocation of SREBP2 in hepa-
tocytes isolated frommice fed either NCD (Fig. 5b, c) or HFD (Fig. 5d, e).
To determine whether AMPK is required for the effects of irisin on
cholesterol synthesis in hepatocytes, compound C was used to block
the activation of AMPK. As shown in Fig. 6a, treatment of hepatocytes
with compound C for 1 h dose-dependently blocked the activation of
AMPK induced by irisin. The blockade of AMPK subsequently reversed
irisin-induced reduction of cholesterol contents in hepatocytes isolated
fromboth lean andDIOmice (Fig. 6b). Again, triglyceridewas not affect-
ed by irisin despite that it was dose-dependently increased by com-
pound C (Fig. 6b). Compound C at a dose of 10 μM was used in the
Fig. 5. Effects of irisin on AMPKα and SREBP2 in primary hepatocytes. Primary hepatocytes were isolated from either lean or DIO mice and treated with irisin (10 nM) in the presence or
absence OA (125 μM). a. Time-dependent effect of irisin on AMPKα phosphorylation. b. SREBP2 content of cytosolic and nuclear fractions of hepatocytes from lean mice analyzed via
Western blot. c. Immunoﬂuorescent staining of hepatocytes from lean mice. d. SREBP2 content of cytosolic and nuclear fractions of hepatocytes from DIO mice analyzed via Western
blot. e. Immunoﬂuorescent staining of hepatocytes from DIO mice. ***P b 0.001 vs blank control; ###P b 0.001 vs OA. Shown is the representative of at least 3 experiments.
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effects of irisin onmRNA levels of Srebf2,Hmgcr andHmgcs (Supplemen-
tal Fig. 3). As shown in Fig. 6c and d, blockade of AMPK activity by com-
pound C completely attenuated the inhibition of SREBP2 nuclear
translocation induced by irisin in the presence or absence of OA as re-
vealed by Western blot analysis of the cytosolic and nuclear fractions
of hepatocyte proteins and immunoﬂuorescent staining. Consistently,
knockdown of AMPKα1 abolished the repression of nuclear SREBP2
translocation (Fig. 7a) and cholesterol accumulation (Fig. 7b) evoked
by irisin in HepG2 cells. Consistently, the inhibitory effect of irisin on
mRNA expression of SREBF2, HMGCR and HMGCS was signiﬁcantly
blocked by inhibition of AMPK by AMPKα1 knockdown (Fig. 7c). There-
fore, blockade of irisin-induced activation of AMPK reversed its inhibi-
tion on SREBP2 nuclear translocation and subsequent suppression of
cholesterol synthesis.
4. Discussion
Our study demonstrated that irisin could inhibit hepatic cholesterol
synthesis via AMPK-dependent inhibition of SREBP2 and its down-
stream target genes. Irisin increased the phosphorylation of AMPKα in
hepatocytes. Blockage of irisin-induced AMPK activation by compound
C or knockdown of AMPKα1 reversed the suppressive effects of irisin
on: 1) hepatic cholesterol synthesis; 2) mRNA expression of SREBP2and its downstream target genes critical for cholesterol synthesis; and
3) nuclear translocalization of SREBP2.
Previous studies have indicated that irisin could improve dyslipid-
emia and hepatic steatosis in mice (Xiong et al., 2015). The decrement
of lipid accumulation in hepatocytes was proposed to result mainly
from the suppression of triglyceride synthesis (Park et al., 2015). In cul-
tured AML12 hepatocytes, recombinant irisin signiﬁcantly reduced the
PA-induced lipid accumulation, and inhibited the PA-induced increase
in lipogenic markers ACC and FAS at the mRNA and protein levels
(Park et al., 2015). Our studies identiﬁed suppression of cholesterol syn-
thesis as an alternative pathway for irisin to reduce lipid content in he-
patocytes. This conclusion is supported by following observations:
1) Administration of irisin reduced the hepatic lipid contents measured
by Oil-red staining in lean and obese mice; 2) In mice and cultured he-
patocytes, irisin decreased levels of hepatic cholesterol, while demon-
strated no effect on triglyceride contents; 3) Irisin inhibited SREBP2
and its target genes HMGCS2 and HMGCR, a key transcriptional factor
and the rate-limiting enzymes for cholesterol synthesis respectively;
4) The effects of irisin on genes related to triglyceride synthesis and β-
oxidation were negligible in hepatocytes. There exist two possible ex-
planations for the conﬂicting observations: different cell models and
sources of irisin used. In the studies by Park et al. (Park et al., 2015),
AML12 mouse hepatocyte cell line was used. This cell line expresses
high levels of human transforming growth factor α (TGFα). Whether
Fig. 6. Compound C blocked the effects of irisin on AMPKα and SREBP2. Primary hepatocytes were isolated from either lean or DIO mice and treated with compound C for 1 h prior to the
addition of irisin (10 nM) with or without OA (125 μM). a. Compound C dose-dependently reversed the phosphorylation of AMPKα induced by irisin. b. Cholesterol and triglyceride
contents in hepatocytes after compound C and irisin treatment. *P b 0.05, **P b 0.01, ***P b 0.001 vs irisin. c. SREBP2 contents of cytosolic and nuclear fractions of hepatocytes treated
with compound C, irisin and/or OA. d. Immunoﬂuorescent staining of SREBP2 in hepatocytes treated with compound C, irisin and/or OA. ***P b 0.001 vs vehicle control; ###P b 0.001
vs OA. Shown is the representative of 3 experiments. CC, compound C.
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sponse to irisin remains to be explored. Theoretically, the preparation of
irisin may affect its biological functions. This potential is unlikely be-
cause we observed no difference in the suppression of cholesterol syn-
thesis between recombinant irisin-Fc and synthetic irisin.
While good progress has been made in identifying the physiological
actions of irisin, its receptor and intracellular signalingpathway remainslargely unknown. Previous studies have shown that irisin may activate
AMPK, PI3K/AKT, or p38 MAPK and ERK (Liu et al., 2015b; Yang et al.,
2015; Zhang et al., 2014; Lee et al., 2015) in skeletal muscle cells, hepa-
tocytes and adipocytes. Our studies also suggest the presence of a
functional receptor for irisin in hepatocytes. Activation of this receptor
by irisin may stimulate AMPK activity, leading to the subsequent sup-
pression of SREBP2 expression and nuclear translocalization. This
Fig. 7. Knockdown of AMPKα1 abolished the effects of irisin on cholesterol synthesis in
HepG2 cells. HepG2 cells were transfected with siAMPKα1 and stimulated with irisin
(10 nM) 48 h later. a. HepG2 cells were treated with irisin for 12 h. Cytosolic and nuclear
proteins were analyzed by Western blot. b. HepG2 cells were stimulated with irisin for
24 h and measured for cholesterol and triglyceride content. c. HepG2 cells were stimulated
with irisin for 24 h. mRNA levels of PRKAA1 (AMPKα1) and cholesterol synthesis related
genes were analyzed by real-time PCR. *P b 0.05, **P b 0.01 vs Scrambled; ###P b 0.001 vs
Scrambled + Irisin. Shown is the representative of 3 experiments.
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AMPK could phosphorylate SREBP2 to reduce SREBP2 precursor cleav-
age and nuclear translocalization (Liu et al., 2015a). Although activation
of AMPK has been demonstrated to suppress hepatic lipid synthesis and
to promote fatty acid β-oxidation by phosphorylating SREBP1c (Liu
et al., 2015a; Ma et al., 2015; Elhanati et al., 2013; Samovski et al.,
2015; Chen et al., 2014; Lee et al., 2012), our studies did not detect con-
sistent change in the levels of triglyceride, SREBP1c and its downstream
target genes. A much higher dose of irisin may be required for its effect
on triglyceride synthesis. Instead, SREBP2 transcription and nuclear
translocalization in hepatocytes were signiﬁcantly attenuated upon ac-
tivation of AMPK by irisin. Themolecularmechanismunderlying the se-
lection of SREBP2 over SREBP1 upon activation of irisin receptor in
hepatocytes is currently unknown.
Emerging evidence has indicated that cross talks between organs are
critical for energy homeostasis. The present studies suggest a direct
communication between the skeletal muscle and liver via irisin. Our
study also provides signiﬁcant evidence that hepatocytes are targets
for irisin in term of the regulation of hepatic cholesterol metabolism.
Conditioned medium from C2C12 myocytes overexpressing FNDC5 sig-
niﬁcantly attenuated cholesterol synthesis in cultured hepatocytes.
Other studies also support the concept that irisin may serve as an im-
portant cross-organ messenger linking skeletal muscle with the brain,
adipose tissue and the cardiovascular system to integrate the exercise
with the physiological activities in these organs (Wrann et al., 2013;Huh et al., 2014; Xiong et al., 2015; Song et al., 2014; Wu et al., 2015;
Zhu et al., 2015; Zhang et al., 2015). Importantly, irisin acts in concert
with ﬁbroblast growth factor 21 to promote adipocyte browning and
thermogenesis in humans (Lee et al., 2014). This result indicates that
cross talk between skeletal muscle and adipose tissue may be critical
for the control of adiposity. Taken together, all these observations sug-
gest that irisin is an important molecule linking the skeletal muscle
with the adipose tissue and liver to integrate lipid metabolism.
Despite the signiﬁcant reduction in hepatic cholesterol, irisin at the
dose used in the study demonstrates no effect on the insulin sensitivity
in either lean or high fat diet induced obese mice. The mechanism un-
derlying the dissociation effects of irisin on hepatic cholesterol and glu-
cose metabolism is currently unknown. Whether the dose of irisin
contributes to this discrepancy remains to be explored.
In conclusion, our studies indicate that irisin inhibits hepatic choles-
terol synthesis via the mechanism dependent of AMPK-SREBP2 signal-
ing. This ﬁnding may shed light on the treatment of diseases related to
hypercholesterolemia, such as atherosclerosis.
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